<DOC>
	<DOCNO>NCT03029780</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy different administration regimens nivolumab plus ipilimumab subject renal cell carcinoma .</brief_summary>
	<brief_title>An Investigational Immuno-Therapy Safety Efficacy Study Multiple Administration Regimens Nivolumab Plus Ipilimumab Subjects With Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Advanced Renal Cell Carcinoma Must full activity , limited , must able walk carry light activity light house work office work Must least 1 lesion measurable disease Subjects active central nervous system metastases Subjects receive prior therapy checkpoint inhibitor Subjects active , know suspected autoimmune disease Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>